
Orally administered PCSK9 inhibitor an upcoming option?
MK-0616, an oral PCSK9 inhibitor, met its primary endpoint in a Phase 2 study, significantly reducing LDL cholesterol levels in patients with hypercholesterolemia at doses of 6 mg to 30 mg compared to placebo. ApoB and non-HDL cholesterol levels have also been reduced. “These data support the further development of MK-0616, which may improve access […]